Search Results for "ipilimumab"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for ipilimumab. Results 11 to 13 of 13 total matches.
See also: Yervoy
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
, ipilimumab, or dacarbazine)
until disease progression or unacceptable toxicity
occurred (except ipilimumab ...
The FDA has approved tebentafusp-tebn (Kimmtrak –
Immunocore), a first-in-class bispecific gp100
peptide-HLA-directed CD3 T-cell engager, for
treatment of HLA-A*02:01-positive unresectable or
metastatic uveal melanoma in adults.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e107-8 doi:10.58347/tml.2024.1705f | Show Introduction Hide Introduction
Cobimetinib (Cotellic) for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
plus ipilimumab (Yervoy) has also
been effective for treatment of unresectable or metastatic
melanoma ...
The FDA has approved the mitogen-activated
extracellular signal-regulated kinase (MEK) inhibitor
cobimetinib (Cotellic – Genentech) for use in combination
with the BRAF kinase inhibitor vemurafenib
(Zelboraf) for treatment of unresectable or metastatic
melanoma with a BRAF V600E or V600K mutation.
Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
plus ipilimumab (Yervoy) is an alternative.
Key Points: Tislelizumab (Tevimbra)
▶ Description ...
The FDA has approved tislelizumab (Tevimbra –
BeiGene), a programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that did not include a programmed death ligand-1
(PD-L1) inhibitor.
Med Lett Drugs Ther. 2024 May 13;66(1702):e85-6 doi:10.58347/tml.2024.1702h | Show Introduction Hide Introduction